Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.

Late Thursday, New York-based Warburg announced an agreement to buy ECN, run by entrepreneur and chief executive officer ...